Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts